RE: Pre|CISION platform works17 Oct 2023 10:23
Just a reminder that, as per the patents that are the IP for pre|CISION, this platform can be used to target drugs to ANY tissue in which FAP has been upregulated, not just epithelial cell cancer tumours. Opportunities for prodrugs targetting inflammation, fibrosis and wound healing have yet to be exploited.
US9737556B2 (granted patent)
Anticipated expiration: 2035-06-15
Title: FAP-activated therapeutic agents, and uses related thereto
Abstract: Disclosed are prodrugs of anthracyclines (such as doxorubicin) and derivatives thereof that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of “warhead” anthracycline or anthracycline derivative to FAP-expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compositions comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, undesirable fibrosis, and undesirable inflammation.
Note the last sentence.